The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study
Por:
Amiot, A, Rahier, JF, Baert, F, Nahon, S, Hart, A, Viazis, N, Biancone, L, Domenech, E, Reenears, C, Peyrin-Biroulet, L, Beaugerie, L and Burisch, J
Publicada:
27 ene 2023
Ahead of Print:
1 jul 2022
Resumen:
Background and Aims There are concerns regarding the potential impact of the COVID-19 outbreak on patients with inflammatory bowel disease [IBD]. We report on the impact of the COVID-19 outbreak in a European prospective cohort study of patients with IBD Patients and Methods We prospectively collected data from 5457 patients with IBD nested in the ongoing I-CARE project and still followed up in April 2020, with monthly online monitoring of clinical activity, treatment, imaging and endoscopy. Investigators were also contacted to report incidental cases. Results In total, 233 [4.3%] reported COVID-19 and 12 [0.2%] severe COVID-19, with no COVID-19 deaths. The risk of COVID-19 in patients with IBD was not increased compared to the general population (standardized incidence ratio [SIR]: 1.18, 95% confidence interval [CI] [1.03-1.34], p = 0.009), as well as the risk of severe COVID-19 (SIR: 0.69, 95% CI [0.35-1.20], p = 0.93). We did not observe any negative impact of the different IBD-related medication on the risk of either COVID-19 or severe COVID-19. In 2020, the COVID-19 outbreak resulted in a drastic decrease in endoscopic and imaging procedures from March to May 2020 compared to 2018 and 2019. No impacts on clinical IBD disease activity as well as ongoing treatment were noted. Conclusion No increases in either COVID-19 or severe COVID-19 incidences were observed in patients with IBD. There was no impact of COVID-19 on IBD-related medication and clinical activity. Access to endoscopy and imaging was restricted during the first months of the first COVID-19 outbreak.
Filiaciones:
Amiot, A:
Univ Paris Est Creteil, Henri Mondor Univ Hosp, AP HP, Dept Gastroenterol,EA7375, F-94010 Creteil, France
Rahier, JF:
CHU UCL Namur, Dept Gastroenterol, 1 Av Dr Therasse, Yvoir, Belgium
Baert, F:
AZ Delta, Div Gastroenterol, Roeselare, Belgium
Nahon, S:
Dept Gastroenterol, Montfermeil, France
Hart, A:
St Marks Hosp & Acad Inst, IBD Unit, Harrow, Middx, England
Viazis, N:
Evangelismos Polyklin Gen Hosp Athens, Gastroenterol Dept, Athens, Greece
Biancone, L:
Univ Tor Vergata Rome, Dept Syst Med, IBD Unit, Via Montpellier, Rome, Italy
:
Hosp Badalona Germans Trias & Pujol, Dept Gastroenterol, Badalona, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Reenears, C:
Univ Hosp CHU Liege, Hepatogastroenterol & Digest Oncol, Liege, Belgium
Peyrin-Biroulet, L:
Nancy Univ Hosp, Dept Gastroenterol, Vandoeuvre Les Nancy, France
Lorraine Univ, Inserm NGERE U1256, Vandoeuvre Les Nancy, France
Beaugerie, L:
Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, St Antoine Univ Hosp, AP HP,Dept Gastroenterol,INSERM, Paris, France
Burisch, J:
Univ Copenhagen, Hvidovre Hosp, Med Div, Gastrounit, Hvidovre, Denmark
Green Submitted, Bronze
|